Department of Interventional Radiology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Eur J Gastroenterol Hepatol. 2024 Oct 1;36(10):1230-1237. doi: 10.1097/MEG.0000000000002822. Epub 2024 Jul 15.
To investigate the feasibility and long-term outcomes of hepatic vein (HV) recanalization using intrahepatic collateral pathways in patients with Budd-Chiari syndrome (BCS) with HV obstruction.
Clinical data of 29 BCS patients with HV obstruction and intrahepatic collateral pathways were reviewed. All patients underwent HV recanalization through the intrahepatic collaterals. Follow-up was performed at 1, 3, 6, and 12 months after treatment and annually thereafter. Cumulative patency and survival rates were assessed using Kaplan-Meier curves. The independent predictors of patency were determined using a Cox regression model.
HV recanalization was successful in 28 of the 29 patients (96.6%), with no complications. Of the 28 cases, simultaneous recanalization of the accessory HV and right HV was achieved in 11 patients, accessory HV and middle HV in six, accessory HV and left HV in three, right HV and middle HV in five, and left HV and middle HV in three. Twenty-eight patients were followed from 4 to 87 (mean, 53.6 ± 26.7) months after treatment, and six patients developed reocclusion. The overall cumulative 1-, 3-, 5-, and 7-year primary HV patency rates were 96.3, 82.9, 74.6, and 59.7%, respectively. The cumulative 1-, 3-, 5-, and 7-year survival rates were 100, 95.8, 95.8, and 86.3%, respectively.
Interventional treatment of HV obstruction in BCS patients through intrahepatic collateral approaches is well tolerated and feasible and can result in excellent long-term patency and survival rates.
探讨经肝内侧支途径治疗肝静脉(HV)阻塞型布加综合征(BCS)患者的可行性及长期疗效。
回顾性分析 29 例 HV 阻塞伴肝内侧支的 BCS 患者的临床资料,所有患者均经肝内侧支途径行 HV 再通术。治疗后 1、3、6、12 个月及此后每年进行随访,采用 Kaplan-Meier 曲线评估累积通畅率和生存率,采用 Cox 回归模型分析影响通畅率的独立预测因素。
29 例患者中 28 例(96.6%)HV 再通成功,无并发症发生。28 例患者中,11 例同时再通副肝静脉和右肝静脉,6 例再通副肝静脉和中肝静脉,3 例再通副肝静脉和左肝静脉,5 例再通右肝静脉和中肝静脉,3 例再通左肝静脉和中肝静脉。28 例患者的随访时间为 4~87 个月(平均 53.6±26.7 个月),6 例患者发生再闭塞。总的 1、3、5、7 年 HV 通畅率分别为 96.3%、82.9%、74.6%和 59.7%,1、3、5、7 年生存率分别为 100%、95.8%、95.8%和 86.3%。
经肝内侧支途径治疗 HV 阻塞型 BCS 患者是一种安全、可行的方法,可获得良好的长期通畅率和生存率。